Introduction: Although anaerobic bacteria have been detected in abundance in the CF airways, the impact their presence and abundance has on lung function and inflammation is unclear. Objectives: To investigate the relationship between aerobic and anaerobic bacterial colony counts (CC), lung clearance index (LCI), FEV 1 and systemic inflammation in clinically stable CF child and adult patients. Methods: Sputum was collected from CF patients and community composition and bacterial abundance was analysed using extended aerobic and anaerobic culture. All subjects completed spirometry and multiple breath washout using 0.2% SF 6 and a modified Innocor™ device to obtain LCI. Blood C-reactive protein, (CRP) was measured by turbidimetric immunoassay. Spearman's rank correlation coefficient was used to assess relationships. Results: Aerobic and anaerobic bacteria were detected in sputum samples from all 29 CF patients studied. A significant negative correlation between total anaerobic CC and LCI (r = −0.54; p = 0.002) was observed. The relationship between total anaerobic CC and FEV 1 % predicted (r = 0.29; p = 0.13) was not significant. Similarly, the relationship between total aerobic CC, LCI (r = −0.32; p = 0.09) and FEV 1 % predicted (r = 0.27; p = 0.16) was not significant. In a subgroup of patients (15/29; 52%), a significant negative correlation was observed between total anaerobic CC and CRP levels (r = −0.56, p = 0.03).
WS20.6 The use of LCI as an effective tool for monitoring clinical response to ivacaftor therapy in CF patients with at least one G551D-allele Objectives: To assess the use of Lung Clearance Index (LCI) as a tool for monitoring pulmonary response to ivacaftor therapy. Methods: Ivacaftor therapy became standard in NI in 2013 for CF patients with one G551D-CFTR allele, positive sweat chloride and/or evidence of sino-pulmonary disease. Data were collected retrospectively on all adults and children on ivacaftor in NI. LCI measurements had been recorded pre-treatment, at 1 and 6 months on treatment, along with FEV1. Results: 22 patients were eligible for inclusion, 15 adults and 8 children. Data were complete on 7 children and 7 adults at baseline and at 1 month. Due to lack of sufficient data, analysis was not carried out in the adults at 6 months. Mean baseline LCI: adults 11.15 (range 8-15.8); children 9.07 (range 6.54-10.8). Mean LCI after 1 month of treatment: adults 10.93 (range 8-13.77); children 7.68 (range 6.57-8.76). Mean LCI after 6 months of treatment: children 7.8 (range 6.12-10.73).
Drop in LCI correlated with increase in FEV1. Many of the children had normal or near normal % predicted FEV1 with a mean FEV1 of 84.1% (71-105%) at baseline, 101.5 (72-150%) at 1 month and 96.3% (66-126%) at 6 months. Conclusion: Mean LCI improved in adults and children after 1 month of ivacaftor therapy and was sustained in children at 6 months. LCI may be a useful tool for monitoring the effectiveness of ivacaftor therapy especially in those with normal FEV1.
